Genesis

Over seven years ago the decision was made to develop a nutraceutical that could increase circulating primitive cells with the hope that it could improve overall wellness and facilitate hematopoietic stem cell treatments in the United States where incubation of hematopoietic stem cells is not allowed for human autologous treatments. The product was developed to increase circulating primitive cells and it is named Xcellara™. Xcellara™ is not a drug but a combination of phytonutrients processed using a proprietary system and equipment.

As testing and experiments progressed, a significant body of anecdotal information came to light and the decision was made to take testing of the product to the next level. In order to do so, a team of world-class Medical Doctors specializing in pharmaceutical testing and toxicology were brought together. 

Our Clinical Team

Our advisory team consisted of 3 highly accomplished physicians with impressive CVs and major clinical research experience with global companies. They are: A retired Harvard Medical School professor who, over 20 years ago, sold his ear nose and throat practice and began a new career developing effective human clinical trials. The next member is a Medical Doctor from China who has a PhD in toxicology and is a professor at the State University of New York in Albany. The third member is a Medical Doctor who graduated from medical school in Saint Petersburg, Russia and has worked for over 20 years in the pharmaceutical industry also working on human clinical trials. 

Initial Research — Proof Of Concept

The obvious question regarding any new product is: Does it work? Our first step was a very simple proof of concept test. Three healthy adults with no illness and normal blood tests were selected. Their blood was drawn and the primitive cells counted to determine a baseline. All three were then given Xcellara™ and two hours later their blood was drawn and the cells counted again. The results showed a significant increase in circulating primitive cells and while this is not a conclusive test, when considered with the known anecdotal information, it was enough to justify a Human Clinical Trial. (fig 1) 

Confirmation - Multiple Studies For Multiple Human Conditions All Generating Superior Outcomes 

1. Human Clinical Trial. The Advisory Team developed a versatile protocol that would be acceptable in the United States, Europe and Asia. An outside Clinical Data Management company was hired to do the randomization and control the data including the data collection process. Protocols for a Human Clinical trial were written and an IRB was approved. The trial was a randomized, double blind, placebo controlled Human Clinical Trial managed by an outside Clinical Data Management company.

All participants were thoroughly screened and given physicals including blood tests to assure they were healthy and all blood work was within acceptable limits. The blood tests were completed on each person prior to the test, at two weeks, four weeks, and two weeks after the trial was completed and measured circulating primitive cells and the following: WBC, RBC, Hb, HCT, MCV, MCH, MCHC, PLT, LYMPH%, MONO%, NEUT%, EO%, BASO%LYMPH%, LYMPH#, MONO#, NEUT#, EO#, BASO#, RDW-CV, RDW-SD, PDW, MPV, PCT, TP, ALB, A/G, TBIL, DBIL, ALT, ALP, CRE, UREA, GLU, IgM, IgA, IgG, CD8, CD4, CD3, CD4/CD8The participants were given an escalating dose beginning at one fourth the recommended serving for one week, then one half the recommended serving for one week, then three fourths of the recommended serving for one week, and finally the full serving for one week.

Cell counts were performed along with the blood test listed above. Day 0 a baseline was determined for each participant. After two weeks the average increase in circulating primitive cells was 117.9%, after four weeks it was 268.8%. (Fig 2)

2. Cancer Cell Line Assay. Following the human clinical trial, additional testing was done on Xcellara™. Among the first were two assays, CCK-8 and SRB to determine the effect Xcellara™ had on selected cancer cell lines. The results of CCK-8 and SRB experiments suggest that Xcellara™ extracts may have anticancer effects. At the cellular level Xcellara™ showed significant inhibitory effects on the cell growth of A549 (non-small cell lung cancer), SGC-7901 (Stomach cancer), HT-29 (colon cancer), and PC-3 (prostate cancer) cancer cells. (Figs 3 and 4) 

3. Anti-Aging. The next tests were done on C. elegans. The test was used to determine if Xcellara™ had anti-aging properties. Pods of 90 C. elegans were used as control and others were given Xcellara™. The results showed the lifespan of C. elegans was significantly prolonged with Xcellara™. Similar results were obtained from experiments with both liquid media and solid agar plates. (fig 5) 

4. Heavy Metal Toxicity Resistance. Further testing with C. elegans in the heavy metal toxicity resistance experiment, the resistance of C. elegans to Cr6+ toxicity cultured in Xcellara™ extracts was significantly increased in comparison to the controls. 

5. Anti-Oxidant. In anti-oxidation experiments, the survival rate of the C. elegans cultured in Xcellara™ to H2O2 treatment was significantly increased.

6. Heat Stress Resistance. In the 34° Cheat stress experiments, the survival rate of C. elegans was increased with Xcellara™.

7. Wound healing in Mice. A study was done to determine if any wound healing benefits were derived from the product. Three points were measured, lesion size, inflammation, and necrosis. All groups were acclimated for one week followed by one week either being fed Xcellara™ or a saline solution. The Xcellara™ group showed significant improvement over the control group in all three areas as shown in fig 6. 

8. Skin Repair – Pain Relief. Similar tests were done on mice for skin repair and nerve damage pain relief. The Skin Repair test showed Xcellara™ treatment could facilitate the skin wound healing process and the Nerve Damage test demonstrated an analgesic effect of Xcellara™ as evidenced by its capability of curtailing the decrease of pain threshold caused by sciatic nerve ligation-induced injury. These results suggest that Xcellara™ formula could be developed as pain reliever to promote nerve injury repair in conditions such as sciatic nerve injury.

Bottom Line: Xcellara™ works and like Stephen Hawking has repeatedly said...

“...Stem cell research is the key to developing cures for degenerative conditions”

Animal Testing—Horses, Hogs & Farm Animals  

Horses: All ingredients in Xcellara™ have been fed to horses for many years with no negative side effects. Based upon those results, the product was given in low doses to race horses in the United states and overseas. The doses were gradually raised until an effective dose was determined. Hundreds of horses have now taken the product, with a slight formula modification to increase the efficacy for horses (Equine Regen® Plus), and no bad side effects have been noted. The horses have been mostly performance horses, thoroughbreds, polo ponies, cutting horses, and barrel racers. Anecdotal comments by horse owners have noted many benefits including, quicker recovery after exercise, horse puts forth more effort yet is still more manageable, hoof strength improved.

To confirm product safety at high doses, under the direct supervision of a veterinarian in Aiken, South Carolina, horses were fed 5 times the recommended daily serving for three months. Complete blood work was done before the trial started and at one month, two months, and three months. Only healthy horses were used in the trial and at the end of the trial all horses blood work showed no adverse effects. The product is not administered on a strict mg/Kg basis; it is recommended that 10 grams a day be given to adult horses. The horses in the trial weighed between 900 and 1,100 lbs. The normal dosage for the horses in the trial was from 20 to 24 mg/Kg and at 5 times the daily dosage the horses received between 100 and 120 mg/Kg. The veterinarian’s observations at the completion of the trial was that all horses appeared to have a shinier coat, the horses responded better to riders and grooms, hoof growth was significantly accelerated, hoof quality was significantly improved, and several had put on additional weight in what appeared to be more muscle.

The increase in circulating primitive cells was a surprise...ranging from 957% to 1,524%. (Fig 7)

Laminitis. There have been no scientific tests for efficacy related to laminitis. However, there have been many incidences in both the United states and overseas where severe cases of laminitis that have not responded to long term treatment have gone away after one to three months on the product. Additional studies need to be done to confirm this is not coincidence.

Hogs. We conducted a four-week study on young show hogs based on a client request. All hogs were healthy and in the 50 lb range when the trial started. The trial was a double blind, placebo controlled test to determine what if any effect the Xcellara™ would have on the hogs. The blood test from the hogs showed no blood issues as a result of the trial and circulating primitive cells significantly increased. Hogs in the Xcellara™ group put on more weight than the other groups. It is our opinion that currently due to the cost of the product it is not viable for food animals.

Bottom Line: Based on multiple tests in multiple countries, Xcellara™ works on Humans, Horses, Hogs, Dogs, Mice & Farm Animals 

Man’s Best Friend—Along With Veterinarians, Dog Trainers, Clinicians & Pet Parents—Know That Our Xcellara™ Infused Pawpa™ Regen Premium Dog Treats Helps Build Healthier, Happier & More Active Dogs! 

Shortly after we developed our equine product we began receiving correspondence from people who had given the human version, Xcellara™, to their dogs and they were praising the benefits. While we were confident that the product posed no threat to the dogs, we felt we needed to immediately do testing to confirm our belief. The trial was performed on 20 healthy dogs that were under the constant supervision of a veterinarian in Aiken, South Carolina. The dogs were given blood test measuring over 20 aspects of the blood prior to being placed on the Xcellara™ product and seven weeks later. All blood work showed no adverse effects. (Fig 8)

Due to time pressure and logistical issues, circulating primitive cells were not counted. The Veterinarian in charge made some observations that were all positive related to coat appearance, stamina, recovery, and responsiveness. 

The results of another study with dogs in South Carolina closely resembled the similar study with humans. The average percent increase in circulating primitive cells after two weeks was 96.2% and at the end of four weeks the average percent increase was 281.3% The Veterinarian observed improvement in the 5 major areas, Appearance, Performance, Behavior, Attitude, and Responsiveness. 

Dog Treats. While the results with dogs has been very rewarding, getting a dog to take a capsule or consume a dry powder is not always easy. That is why it was decided to place the product in a soft treat. The treat is named it PawPa™ Regen Dog Treats.

The Apbartm Guide To Rating The Well-Being Of Your Dog

After discussions with many owners and Vets, a corporate medical advisor came up with a very creative way to judge the improvement in a pet. It was developed for dogs but works well with other pets also.

In 1952, Dr. Virginia Apgar introduced an acronym to describe a rating system, or the health status, of newborn human babies. APGAR denotes Appearance, Pulse, Grimace, Activity, and Respiration. Today, the APGAR scale is widely used in the majority of hospitals in the United States and most developed countries. Consequently, many parents know that a high, APGAR is associated with good health.

The APBARTM for animals rating system was developed in order to help measure the improvement in dogs as they benefit from taking the PawPaTM Regen Treats. As dogs mature, there is a natural decline in the areas measured by the APBARTM – Appearance, Performance, Behavior, Attitude, and Responsiveness. Owners notice that when their dog is given PawPaTM Regen Treats every day, there is an improvement in the APBARTM score. The effect may be seen in as little as a few days. If an animal is young and healthy it may take longer to see the improvement. 

When dogs are given our premium dog treats on a daily basis, there is an associated improvement in their APBARTM rating that may be seen in as little as a few days. Young, healthy dogs may take longer to show the improvement. Further, data shows that our premium dog treats are far superior to traditional treats, including national brands, because our products dramatically increases a dog’s 5 key APBARTM metrics... 

We’re proud that ours is the only dog treat that’s APBARTM rated and can make this claim.

In Summary—Years of Clinical Research on Humans, Horses, Farm Animals & Dogs— prove beyond a doubt that Xcellara™ is a safe, breakthrough product that works!

BioAdaptives, Inc. is a science based publicly traded company, that specializes in the creation of highly efficacious nutraceutical/stem cell regenerative products. Supported by a world class clinical Team, our mantra is very simple: Better Science—Better Nutrition™.